Why the study?
Does sequential radionuclide angiocardiography effectively monitor subclinical cardiotoxicity in women receiving doxorubicin for gynecologic malignancies?
Does sequential radionuclide angiocardiography effectively monitor subclinical cardiotoxicity in women receiving doxorubicin for gynecologic malignancies?
Sequential radionuclide angiocardiography is a useful tool for monitoring doxorubicin-induced cardiotoxicity and guiding therapy continuation or cessation.
Answers are grounded in this paper and cite their sources.
May support extended doxorubicin dosing with normal CEF in select patients; leaves open randomized confirmation before broader adoption.
A prospective study was carried out to evaluate the role of radionuclide angiocardiography (CEF) in accessing subclinical cardiotoxicity secondary to Adriamycin (doxorubicin) therapy in 73 women with gynecologic malignancies. Based on the findings of this study, the authors conclude that all patients should have an initial CEF before Adriamycin therapy. In patients with an initial CEF of greater than or equal to 55, frequent determinations are not necessary unless there is a significant decrease from the initial CEF. Patients with low normal initial CEF or significant difference between the initial CEF and minimum CEF should have CEF studies performed at more frequent intervals. Patients who develop below normal CEF should have Adriamycin withheld and CEF should be repeated at more frequent intervals. If the CEF returns to normal Adriamycin therapy can be reinstated. Patients requiring continuation of Adriamycin past 550 mg/m2, can safely do so as long as the CEF values remain normal.
No takes yet. Share an insight, caveat, or question.
Piver et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: